Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma

Gut

Volumn 63, Issue 9, 2014, Pages 1457-1467

  Chang, Wenjun ^a   Gao, Xianhua ^b   Han, Yifang ^a   Du, Yan ^a   Liu, Qizhi ^b   Wang, Lei ^c   Tan, Xiaojie ^a   Zhang, Qi ^a   Liu, Yan ^a   Zhu, Yan ^b   Yu, Yongwei ^b   Fan, Xinjuan ^c   Zhang, Hongwei ^a   Zhou, Weiping ^a   Wang, Jianping ^c   Fu, Chuangang ^b   Cao, Guangwen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL DECISION MAKING; COHORT ANALYSIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; GRB2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ITGB1 GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; ONCOGENE; POSTN GENE; PRIORITY JOURNAL; PTPN11 GENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VALIDATION PROCESS; WESTERN BLOTTING;

COLORECTAL CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CHEMOTHERAPY, ADJUVANT; CHINA; COLECTOMY; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905563250     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305475     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Quirke P, Williams GT, Ectors N, et al. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol 2007;8:651-7. (Pubitemid 46995637)
3. Deschoolmeester V, Baay M, Specenier P, et al. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010;15:699-731.
4. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452:564-70. (Pubitemid 351483370)
5. Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut 2012;61:1560-7.
6. Popovici V, Budinska E, Tejpar S, et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012;30:1288-95.
7. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012;12:260.
8. Merlos-Suárez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011;8:511-24.
9. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29:17-24.
10. Oh SC, Park YY, Park ES, et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012;61:1291-8.
11. Mettu RK, Wan YW, Habermann JK, et al. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 2010;25:219-28.
12. Bandrés E, Malumbres R, Cubedo E, et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep 2007;17:1089-94.
13. Peng J, Wang Z, Chen W, et al. Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer. Int J Colorectal Dis 2010;25:1277-85.
14. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
15. Jorissen RN, Gibbs P, Christie M, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
16. Fritzmann J, Morkel M, Besser D, et al. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 2009;137:165-75.
17. Watanabe T, Kobunai T, Sakamoto E, et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009;115:283-92.
18. Lin YH, Friederichs J, Black MA, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007;13(2 Pt 1):498-507. (Pubitemid 46225355)
19. Laiho P, Kokko A, Vanharanta S, et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007;26:312-20. (Pubitemid 46095743)
20. Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685-91. (Pubitemid 46630932)
21. Barrier A, Lemoine A, Boelle PY, et al. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005;24:6155-64. (Pubitemid 43080065)
22. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005;129:874-84. (Pubitemid 41242680)
23. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005;23:3526-35.
24. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-91. (Pubitemid 38406833)
25. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-71. (Pubitemid 41079793)
26. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011;29:4620-6.
27. Sveen A, Ågesen TH, Nesbakken A, et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res 2012;18:6001-10.
28. Sanz-Pamplona R, Berenguer A, Cordero D, et al. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS One 2012;7:e48877.
29. Tsuji S, Midorikawa Y, Takahashi T, et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer 2012;106:126-32.
30. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131.
31. Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One 2010;5:e15543.
32. Rimm DL, Nielsen TO, Jewell SD, et al. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol 2011;29:2282-90.
33. Ilyas M, Grabsch H, Ellis IO, et al. Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology 2013;62:827-39.
34. McLornan DP, Barrett HL, Cummins R, et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010;16:3442-51.
35. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J 2010;52:70-84.
36. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9. (Pubitemid 39487712)
37. Wei C, Chen J, Pande M, et al. A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome. J Cancer Res Clin Oncol 2013 doi:10. 1007/s00432-013-1437-x
38. van der Wal GE, Gouw AS, Kamps JA, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg 2012;255:86-94.
39. Park YY, Lee SS, Lim JY, et al. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 2013;8:e60778.
40. Roth AD, Delorenzi M, Tejpar S, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
41. Guo H, Liu W, Ju Z, et al. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 2012;10:56.
42. Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004;10:8229-34. (Pubitemid 40053382)
43. O'Dwyer D, Ralton LD, O'Shea A, et al. The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011;6:e27718.
44. Yu SJ, Yu JK, Ge WT, et al. SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 2011;17:2028-36.
45. Giubellino A, Burke TR Jr., Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets 2008;12:1021-33.
46. Yu GZ, Chen Y, Long YQ, et al. New insight into the key proteins and pathways involved in the metastasis of colorectal carcinoma. Oncol Rep 2008;19:1191-204.
47. Ben QW, Zhao Z, Ge SF, et al. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol 2009;34:821-8.
48. Kikuchi Y, Kashima TG, Nishiyama T, et al. Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem 2008;56:753-64. (Pubitemid 351991088)
49. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004;5:329-39. (Pubitemid 38482069)
50. Malanchi I, Santamaria-Martinez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011;481:85-9.
51. Tai IT, Dai M, Chen LB. Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies. Carcinogenesis 2005;26:908-15. (Pubitemid 41214319)
52. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011;19:629-39.
53. Aceto N, Sausgruber N, Brinkhaus H, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012;18:529-37.
54. Reuter JA, Ortiz-Urda S, Kretz M, et al. Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. Cancer Cell 2009;15:477-88.
55. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.